Home » Healthcare » Pharmaceuticals » Pharmaceutical CRO and CDMO Market

Pharmaceutical CRO and CDMO Market By Service Type (Active Pharmaceutical Ingredient (API) Manufacturing, Small Molecule, Large Molecule, High Potency (HPAPI), Finished Dosage Formulation (FDF) Development and Manufacturing, Solid Dose Formulation, Liquid Dose Formulation, Injectable Dose Formulation, Secondary Packaging )-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Summary
Table Of Content

Actionable Insights Delivered -Pharmaceutical CRO and CDMO Market Size

Positioned with a USD 308.9 billion valuation in 2022, the Pharmaceutical CRO and CDMO Market asserted its global eminence. Set to scale to USD 338.13 billion by 2030, the market’s remarkable Compound Annual Growth Rate (CAGR) of 1.30% (2022-2030) underscores its strategic growth trajectory.

Key Highlights of the Report

The global Pharmaceutical CRO and CDMO market is segmented by service type, research phase, and region. The Active pharmaceutical ingredient (API) manufacturing category led the market by service type, while phase III is the dominating category by research phase.

The largest pharmaceutical market in the world, the United States, generates significant demand for CRO and CDMO services. In North America, CRO and CDMO businesses are well-represented and provide various services. North America’s relatively stable regulatory environment for pharmaceutical research makes it a desirable market for pharmaceutical businesses.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

The growing number of biologics in the pipeline. Biologics are complex molecules that are difficult to manufacture, which creates a demand for CDMOs with expertise in biologics manufacturing. The increasing regulatory requirements for pharmaceutical manufacturing. The regulatory environment for pharmaceutical manufacturing is becoming more stringent, driving the demand for CDMOs to help pharmaceutical companies comply with these requirements.

What Are The Main Drivers Of The Global Pharmaceutical CRO and CDMO Market?

New drugs to treat chronic diseases are becoming more and more necessary as the world’s population ages. The demand for CRO and CDMO services is being fueled by pharmaceutical businesses’ use of these companies to outsource the development and production of new medications. Additionally, the need for CRO and CDMO services is growing as the regulatory environment for pharmaceutical development tightens. These businesses are qualified and experienced to assist pharmaceutical firms in adhering to these rules.

What Are The Major Challenges Faced By The Global Pharmaceutical CRO and CDMO Market?

CRO and CDMO businesses face difficulties as the regulatory environment for pharmaceutical research becomes more strict. These businesses must possess the knowledge and experience necessary to assist pharmaceutical companies in adhering to these requirements.

What Are The Growth Opportunities In The Global Pharmaceutical CRO and CDMO Market?

Pharmaceutical firms are increasingly outsourcing their manufacturing and development tasks to CRO and CDMO firms. This is brought on by the rising cost of developing new drugs, the requirement for highly specialized knowledge, and the desire to concentrate on core capabilities.

Executive Summary

Overview of the Global Pharmaceutical CRO and CDMO Market

The need for new medications is rising, drug research costs are rising, and pharmaceutical corporations continue to outsource their manufacturing and drug development operations, which are the main drivers of this increase. Customizing medical care for each patient’s needs is known as customized medicine, and it is receiving more attention. Due to their ability to support pharmaceutical companies in developing and producing tailored medicines, CRO and CDMO businesses are seeing growing prospects. The market is anticipated to expand further in the upcoming years due to these and other factors.

Market Definition

Contract Research Organization and Contract Development and Manufacturing Organization are two terms used in the pharmaceutical industry. These businesses help pharmaceutical and biotechnology firms at every stage of the development and production of drugs by providing them with outsourced services.

CROs provide a variety of services, such as:

Clinical research: CROs run clinical trials to judge the security and effectiveness of brand-new medications.
Regulatory compliance: CROs assist pharmaceutical firms in meeting regulatory standards for the creation and production of drugs.
Data collection and management: CROs gather and handle clinical trial data. CROs analyze clinical trial data using biostatistics.
Pharmacovigilance: CROs keep an eye on their safety after medications are given the green light for commercialization.

CDMOs provide a variety of services, such as:

Active pharmaceutical ingredients (APIs), which are the molecules that give medications their therapeutic effect, are manufactured by CDMOs.
Development and production of FDFs: CDMOs produce finished dosage forms (FDFs), the finished goods administered to patients.
FDFs are packaged by CDMOs for distribution.
The distribution of FDFs is handled logistically by CDMOs.

In the pharmaceutical sector, CROs and CDMOs are crucial players. They aid pharmaceutical firms in developing and producing new medications more effectively and economically.

Market Insights

The global demand for Pharmaceutical CROs and CDMOs was valued at USD 308.9 Billion in 2022 and is expected to reach USD 338.13 Billion in 2030, growing at a CAGR of 1.30% between 2023 and 2030.
Manufacturing API was the largest market category in 2022, making for 55.6% of the overall market.
Phase III, which comprised 44.2% of the market in 2022, is the largest market segment. The largest market segment is phase III for several reasons. The most expensive and time-consuming phase of drug development is phase III clinical trials, for example.
North America will be the largest market in 2022 since many CRO and CDMO businesses provide a wide range of services.
Due to the complexity of new treatments and the requirement for more clinical studies, drug development costs are increasing. Due to their ability to assist pharmaceutical companies in lowering the cost of drug development, CRO and CDMO businesses are seeing growing potential.

Segmentation by Service Type

Active pharmaceutical ingredient (API) manufacturing category accounted for 55.6% of the market’s overall revenue in 2022, is the largest market segment.
As more novel drugs are approved, there is a rising demand for APIs.
Making APIs is generally inexpensive, making them a desirable choice for pharmaceutical businesses.
Further, there is a growing trend of outsourcing API manufacturing to CDMOs, further driving this market segment’s growth.

Segmentation by Research Phase

Phase III, which in 2022 accounted for 44.2% of the market, is the largest market segment.
The most expensive and time-consuming phase of medication development is phase III clinical trials.
There is a demand for CROs and CDMOs with experience in this field because the regulatory criteria for phase III trials are stricter than those for previous phases.

Segmentation by Region

North America, which accounted for 34.9% of the overall market in 2022, was the largest region globally.
The United States dominates the pharmaceutical CRO and CDMO market in North America.
In addition to having many pharmaceutical firms based here, the US also has a significant number of CRO and CDMO firms.
The United States generally stable regulatory environment for pharmaceutical research makes it a desirable market for pharmaceutical businesses.

In 2022, the pharmaceutical CRO and CDMO market in the United States will be the biggest market globally. Several variables, such as rising new drug demand, rising drug development costs, and increased complexity of drug development, are propelling the growth of the U.S. pharmaceutical CRO and CDMO market. Another market aspect that stands out is the abundance of small and medium-sized competitors. By providing specialized services or concentrating on niche markets, these firms can compete with the bigger competitors in their industry.

In the Asia Pacific region, India’s pharmaceutical CRO and CDMO market is anticipated to grow at the fastest rate. Generic medications are produced in large quantities in India, and there is a rising demand for them on the international market. In addition, as the price of developing new drugs rises, pharmaceutical firms are increasingly outsourcing the development and production of new drugs to CROs and CDMOs to cut costs. Pharmaceutical corporations worldwide are progressively establishing research and development facilities in India and outsourcing drug development and manufacturing tasks to CROs and CDMOs there.

Numerous technological developments have opened up new growth prospects for CRO and CDMO businesses. These involve the application of AI, gene editing, and 3D printing. Data analysis and clinical trial management are two jobs that artificial intelligence (AI) is utilized to automate in drug development and manufacturing. AI is also being utilized to provide new medication development tools and increase production procedures’ effectiveness. New cures for hereditary illnesses are being created via gene editing. Gene editing can also be utilized to develop customized medications catered to the patient’s unique genetic profile. Using 3D printing, it is now possible to make complicated medications that are challenging to make using conventional techniques and innovative drug delivery systems. CRO and CDMO businesses that can adopt these emerging technologies will be well-positioned to thrive.

In recent years, the price of creating a new medicine has continuously grown, and this pattern is anticipated to continue. As a result, pharmaceutical firms are increasingly turning to CROs and CDMOs for assistance in lowering the price of drug development. Additionally, personalized medicine is expanding quickly, opening up new potential for CROs and CDMOs. Personalized medicine involves configuring drug regimens to each patient’s unique genetic profile. Pharmaceutical companies can work with CROs and CDMOs to create individualized medications to increase patient outcomes and lower their risk of adverse events.

Increasing Prevalence Of Chronic Diseases

One of the main forces behind the growth of the pharmaceutical CRO and CDMO market is the rising prevalence of chronic diseases. The World Health Organization (WHO) claims that the greatest cause of mortality and disability worldwide is chronic disease. Globally, chronic diseases caused 74% of deaths in 2020. Heart disease, cancer, diabetes, stroke, and chronic respiratory conditions are a few of the most prevalent chronic diseases. These illnesses frequently require continuing care since they are chronic. The need for cutting-edge therapies rises in tandem with the prevalence of these diseases. New medicines for chronic diseases are developed and manufactured with the help of pharmaceutical CROs and CDMOs. They offer various services, such as clinical research, production, compliance with regulations, and packaging. Pharmaceutical companies can concentrate on their core expertise and introduce novel therapies to the market more swiftly and effectively by outsourcing these services to CROs and CDMOs.

Rising Demand For Generic Drugs

Drugs with generic names are copies of name-brand medications whose patents have expired. They offer the same efficacy and safety as name-brand medications but are often far less expensive. The need for CROs and CDMOs that can help develop and produce generic pharmaceuticals grows along with the demand for these medications. Pharmaceutical firms can work with CROs and CDMOs to develop and produce generic medications more rapidly and effectively, which can assist in lowering the price of these medications. The pharmaceutical CRO and CDMO business has a significant opportunity because of the rising demand for generic medications. CROs and CDMOs can contribute to the global availability and affordability of generic medications for patients by offering pharmaceutical businesses cutting-edge services.

Regulatory Challenges Faced In The Pharmaceutical CRO And CDMO

The market for pharmaceutical CROs and CDMOs is very regulated. Although the regulatory landscape differs from nation to nation, there are some universal rules that all CROs and CDMOs must abide by. These laws include the Data Privacy Regulations, Good Clinical Practices (GCP), and Good Manufacturing Practices (GMP). The regulatory landscape for CDMOs and CROs in the pharmaceutical industry is intricate and dynamic. To comply with the most recent laws, CROs and CDMOs must keep up with them. Additionally, it can be expensive to comply with regulatory standards. To ensure they comply with the most recent legislation, CROs and CDMOs need to invest in resources. CROs and CDMOs may face considerable regulatory difficulties. CROs and CDMOs can reduce the risks and ensure they can continue operating in the pharmaceutical sector by understanding the regulatory environment and taking action to comply with the most recent laws.

Pharmaceutical Companies Outsourcing

The global pharmaceutical CRO and CDMO industry is seeing opportunities due to the outsourcing trend in several different ways. Pharmaceutical firms can lower their manufacturing and development costs through outsourcing. Pharmaceutical companies often have higher overhead costs than CROs and CDMOs. Additionally, it may make the marketing of medicines by pharmaceutical corporations easier. This is so that the drug research and manufacturing process can be streamlined; CROs and CDMOs have the knowledge and experience to do this.

Additionally, it enables pharmaceutical firms to concentrate on their core strengths, such as the discovery and development of new drugs. This can make pharmaceutical firms more competitive and inventive. In the upcoming years, it is anticipated that the outsourcing trend will continue as more and more pharmaceutical companies seek to cut costs and expedite the drug development process. Further opportunities should result from this for the worldwide pharmaceutical CRO and CDMO market.

Rising Cost Of Drug Development

Pharmaceutical businesses often have higher overhead costs than CROs and CDMOs. Pharmaceutical companies can save costs by outsourcing medication development and manufacturing tasks to CROs and CDMOs. The drug research and manufacturing processes can be streamlined thanks to the knowledge and experience of CROs and CDMOs. As a result, pharmaceutical corporations may be able to promote their products more quickly and ultimately save money. Additionally, CROs and CDMOs have the knowledge and experience to guarantee that medicines are produced in accordance with high-quality standards. Pharmaceutical businesses may benefit from avoiding pricey recalls and enhancing their brand in this way. In the upcoming years, drug development costs are anticipated to continue to rise. Various elements, such as the growing complexity of drug discovery, the rising price of clinical trials, and the rising price of pharmaceutical production, bring this on. More and more pharmaceutical corporations are projected to outsource drug research and manufacturing activities to CROs and CDMOs as the cost of drug development rises.

Competitive Landscape

Key Players

The pharmaceutical CRO and CDMO business is extremely competitive on a global scale. Few major companies dominate the market, and these companies offer a wide range of services and have a significant global presence. However, as new competitors from developing nations like China and India enter the industry, it is also becoming more fragmented. The existing players are under pressure because these new firms are providing competitive services and pricing. Some of the major players in the market and their market share are as follows:

Catalent Inc.
Recipharm AB
Jubilant Pharmova Ltd
Patheon Inc. (Thermo Fisher Scientific Inc.)
Boehringer Ingelheim Group
Pfizer CentreSource
Aenova Holding GmbH
Famar SA
Baxter Biopharma Solutions (Baxter International Inc.)
Lonza Group
Tesa Labtec GmbH (TESA SE)
Tapemark
ARX LLC
CMIC Holdings Co. Ltd
LabCorp Drug Development
Syneos Health Inc.
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (Thermo Fisher Scientific Inc.)
PRA Health Sciences Inc. (Icon PLC)
Quanticate Ltd
IQVIA Holdings Inc.
SGS Life Science Services SA
Hangzhou Tigermed Consulting Co. Ltd
Samsung Bioepis Co. Ltd
WuXi AppTec Inc.
Sagimet Biosciences (3V Biosciences Inc.)

Businesses are investing in new technologies to enhance their services and reduce costs. For instance, some businesses spend money on artificial intelligence (AI) to automate processes and boost clinical trial effectiveness.

Companies buy smaller businesses to increase their product offerings and gain access to new capabilities. For instance, IQVIA purchased ICON plc in 2017 to establish itself as the largest CRO globally.

Companies are forming alliances with other businesses to pool resources and knowledge. For instance, WuXi AppTec and Pfizer collaborated to develop and produce a novel medicine for cancer management.

Thermo Fisher Scientific Inc. paid USD 2.8 billion to acquire Binding Site Group, a leading provider of specialist diagnostics, in January 2023. The Binding Site expands the already wide-ranging line of specialist diagnostics offered by Thermo Fisher by introducing ground-breaking innovation in multiple myeloma diagnosis and monitoring. Early diagnosis and wise treatment decisions can greatly impact patient outcomes.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Summary of Key Findings

The rising cost of drug research drives the market, the rising need for novel pharmaceuticals, and the expanding outsourcing tendency.
To keep ahead of this highly competitive industry, the major players are investing money into new technologies, broadening their geographic reach, buying smaller businesses, and forming alliances with other businesses.
The main pharmaceutical CRO and CDMO markets are in North America, Europe, and Asia Pacific.

Future Outlook

The market is anticipated to expand during the upcoming years due to increased outsourcing trends, rising drug development costs, and rising need for new medications.
Large players are anticipated to continue expanding in the industry, while new players from emerging markets are anticipated to appear.
New technologies are also anticipated to enter the market, opening fresh potential for CROs and CDMOs.
The future of the global pharmaceutical CRO and CDMO market is anticipated to be shaped by several key trends, including a growing emphasis on personalized medicine, a growing significance of regulatory compliance, and a growing reliance on technology to speed up drug development and production.

Segmentation

By CRO

Clinical Research Services (CRO)
Preclinical Research Services (CRO)
Clinical Data Management (CRO)
Bioanalytical Testing Services (CRO)
Clinical Trial Logistics and Supply Chain Management (CRO)

By CDMO

Formulation Development (CDMO)
API Development and Manufacturing (CDMO)
Drug Product Manufacturing (CDMO)
Packaging and Labeling Services (CDMO)
Analytical and QC Testing Services (CDMO)

By End-user

Large Size Companies
Medium & Small Size Companies

By Therapy Area

Oncology
Cardiovascular Diseases
Infectious Diseases
Musculoskeletal Disorders
Others

By Region

North America
- U.S
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Data Modelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Pharmaceutical CRO and CDMO Market
2.2. Global Pharmaceutical CRO and CDMO Market, By Service Type
2.3. Global Pharmaceutical CRO and CDMO Market, By Research Phase
2.4. Global Pharmaceutical CRO and CDMO Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Pharmaceutical CRO and CDMO Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Service Type
3.5.2. Research Phase
3.5.3. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Service Type Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Pharmaceutical CRO and CDMO Market, By Service Type
7.1. Global Pharmaceutical CRO and CDMO Market Overview, by Service Type
7.1.1. Global Pharmaceutical CRO and CDMO Market Revenue Share, By Service Type, 2022 Vs 2030 (in %)
7.2. Active Pharmaceutical Ingredient (API) Manufacturing
7.2.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)
7.2.1.1. Small Molecule
7.2.1.1.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)
7.2.1.2. Large Molecule
7.2.1.2.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)
7.2.1.3. High Potency (HPAPI)
7.2.1.3.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)
7.3. Active Pharmaceutical Ingredient (API) Manufacturing
7.3.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)
7.3.1.1. Solid Dose Formulation
7.3.1.1.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)
7.3.1.2. Liquid Dose Formulation
7.3.1.2.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)
7.3.1.3. Injectable Dose Formulation
7.3.1.3.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)
7.4. Secondary Packaging
7.4.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)

8. Global Pharmaceutical CRO and CDMO Market, By Research Phase
8.1. Global Pharmaceutical CRO and CDMO Market Overview, by Research Phase
8.1.1. Global Pharmaceutical CRO and CDMO Market, By Research Phase, 2022 vs 2030 (in %)
8.2. Pre-clinical
8.2.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)
8.3. Phase I
8.3.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)
8.4. Phase II
8.4.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)
8.5. Phase III
8.5.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)
8.6. Phase IV
8.6.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2017-2030 (US$ Bn)

9. Global Pharmaceutical CRO and CDMO Market, By Region
9.1. Global Pharmaceutical CRO and CDMO Market Overview, by Region
9.1.1. Global Pharmaceutical CRO and CDMO Market, By Region, 2022 vs 2030 (in%)
9.2. Service Type
9.2.1. Global Pharmaceutical CRO and CDMO Market, By Service Type, 2017-2030 (US$ Bn)
9.3. Research Phase
9.3.1. Global Pharmaceutical CRO and CDMO Market, By Research Phase, 2017-2030 (US$ Bn)

10. North America Pharmaceutical CRO and CDMO Market Analysis
10.1. North America Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2030(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. North America Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2030(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. North America Pharmaceutical CRO and CDMO Market, by Country, 2017-2030 (US$ Bn)
10.3.1. North America Pharmaceutical CRO and CDMO Market, by Country, 2022 Vs 2030 (in%)
10.3.2. U.S.
10.3.2.1. U.S. Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.2.2. U.S. Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
10.3.2.3. U.S. Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
10.3.3. Canada
10.3.3.1. Canada Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.3.2. Canada Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
10.3.3.3. Canada Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
10.3.4. Mexico
10.3.4.1. Mexico Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.4.2. Mexico Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
10.3.4.3. Mexico Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)

11. Europe Pharmaceutical CRO and CDMO Market Analysis
11.1. Europe Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2030(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Europe Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2030(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Europe Pharmaceutical CRO and CDMO Market, by Country, 2017-2030 (US$ Bn)
11.3.1. Europe Pharmaceutical CRO and CDMO Market, by Country, 2022 Vs 2030 (in%)
11.3.2. Germany
11.3.2.1. Germany Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.2.2. Germany Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
11.3.2.3. Germany Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
11.3.3. France
11.3.3.1. France Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.3.2. France Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
11.3.3.3. France Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
11.3.4. UK
11.3.4.1. UK Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.4.2. UK Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
11.3.4.3. UK Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
11.3.5. Italy
11.3.5.1. Italy Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.5.2. Italy Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
11.3.5.3. Italy Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
11.3.6. Spain
11.3.6.1. Spain Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.6.2. Spain Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
11.3.6.3. Spain Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
11.3.7. Rest of Europe
11.3.7.1. Rest of Europe Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.7.2. Rest of Europe Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
11.3.7.3. Rest of Europe Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)

12. Asia Pacific Pharmaceutical CRO and CDMO Market Analysis
12.1. Asia Pacific Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Asia Pacific Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2030(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Asia Pacific Pharmaceutical CRO and CDMO Market, by Country, 2017-2030 (US$ Bn)
12.3.1. Asia Pacific Pharmaceutical CRO and CDMO Market, by Country, 2022 Vs 2030 (in%)
12.3.2. China
12.3.2.1. China Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.2.2. China Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
12.3.2.3. China Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
12.3.3. Japan
12.3.3.1. Japan Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.3.2. Japan Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
12.3.3.3. Japan Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
12.3.4. India
12.3.4.1. India Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.4.2. India Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
12.3.4.3. India Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
12.3.5. South Korea
12.3.5.1. South Korea Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.5.2. South Korea Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
12.3.5.3. South Korea Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
12.3.6. South-East Asia
12.3.6.1. South-East Asia Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.6.2. South-East Asia Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
12.3.6.3. South-East Asia Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
12.3.7. Rest of Asia Pacific
12.3.7.1. Rest of Asia Pacific Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.7.2. Rest of Asia Pacific Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
12.3.7.3. Rest of Asia Pacific Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)

13. Latin America Pharmaceutical CRO and CDMO Market Analysis
13.1. Latin America Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2030(US$ Bn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. Latin America Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2030(US$ Bn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Latin America Pharmaceutical CRO and CDMO Market, by Country, 2017-2030 (US$ Bn)
13.3.1. Latin America Pharmaceutical CRO and CDMO Market, by Country, 2022 Vs 2030 (in%)
13.3.2. Brazil
13.3.2.1. Brazil Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.2.2. Brazil Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
13.3.2.3. Brazil Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
13.3.3. Argentina
13.3.3.1. Argentina Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.3.2. Argentina Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
13.3.3.3. Argentina Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
13.3.4. Rest of Latin America
13.3.4.1. Rest of Latin America Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.4.2. Rest of Latin America Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
13.3.4.3. Rest of Latin America Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)

14. Middle East and Africa Pharmaceutical CRO and CDMO Market Analysis
14.1. Middle East and Africa Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2030(US$ Bn)
14.1.1. Overview
14.1.2. SRC Analysis
14.2. Middle East and Africa Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2030(US$ Bn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Middle East and Africa Pharmaceutical CRO and CDMO Market, by Country, 2017-2030 (US$ Bn)
14.3.1. Middle East and Africa Pharmaceutical CRO and CDMO Market, by Country, 2022 Vs 2030 (in%)
14.3.2. GCC Countries
14.3.2.1. GCC Countries Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.2.2. GCC Countries Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
14.3.2.3. GCC Countries Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
14.3.3. South Africa
14.3.3.1. South Africa Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.3.2. South Africa Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
14.3.3.3. South Africa Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)
14.3.4. Rest of Middle East and Africa
14.3.4.1. Rest of Middle East and Africa Pharmaceutical CRO and CDMO Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.4.2. Rest of Middle East and Africa Pharmaceutical CRO and CDMO, By Service Type, 2017-2030 (US$ Bn)
14.3.4.3. Rest of Middle East and Africa Pharmaceutical CRO and CDMO, By Research Phase, 2017-2030 (US$ Bn)

15. Company Profiles
15.1. Catalent Inc.
15.1.1. Company Overview
15.1.2. Products/Services Portfolio
15.1.3. Geographical Presence
15.1.4. Financial Summary
15.1.4.1. Market Revenue and Net Profit (2019-2022)
15.1.4.2. Business Segment Revenue Analysis
15.1.4.3. Geographical Revenue Analysis
15.2. Recipharm AB
15.3. Jubilant Pharmova Ltd
15.4. Patheon Inc. (Thermo Fisher Scientific Inc.)
15.5. Boehringer Ingelheim Group
15.6. Pfizer CentreSource
15.7. Aenova Holding GmbH
15.8. Famar SA
15.9. Baxter Biopharma Solutions (Baxter International Inc.)
15.10. Lonza Group
15.11. Tesa Labtec GmbH (TESA SE)
15.12. Tapemark
15.13. ARX LLC
15.14. CMIC Holdings Co. Ltd
15.15. LabCorp Drug Development
15.16. Syneos Health Inc.
15.17. Novotech Pty Ltd
15.18. PAREXEL International Corporation
15.19. Pharmaceutical Product Development LLC (Thermo Fisher Scientific Inc.)
15.20. PRA Health Sciences Inc. (Icon PLC)
15.21. Quanticate Ltd
15.22. IQVIA Holdings Inc.
15.23. SGS Life Science Services SA
15.24. Hangzhou Tigermed Consulting Co. Ltd
15.25. Samsung Bioepis Co. Ltd
15.26. WuXi AppTec Inc.
15.27. Sagimet Biosciences (3V Biosciences Inc.)

List of Figures
FIG. 1 Global Pharmaceutical CRO and CDMO Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Pharmaceutical CRO and CDMO Market Segmentation
FIG. 4 Global Pharmaceutical CRO and CDMO Market, by Service Type, 2022 (US$ Bn)
FIG. 5 Global Pharmaceutical CRO and CDMO Market, by Research Phase, 2022 (US$ Bn)
FIG. 6 Global Pharmaceutical CRO and CDMO Market, by Geography, 2022 (US$ Bn)
FIG. 7 Attractive Investment Proposition, by Service Type, 2022
FIG. 8 Attractive Investment Proposition, by Research Phase, 2022
FIG. 9 Attractive Investment Proposition, by Geography, 2022
FIG. 10 Global Market Share Analysis of Key Pharmaceutical CRO and CDMO Market Manufacturers, 2022
FIG. 11 Global Market Positioning of Key Pharmaceutical CRO and CDMO Market Manufacturers, 2022
FIG. 12 Global Pharmaceutical CRO and CDMO Market Value Contribution, By Service Type, 2022 & 2030 (Value %)
FIG. 13 Global Pharmaceutical CRO and CDMO Market, by Active Pharmaceutical Ingredient (API) Manufacturing, Value, 2017-2030 (US$ Bn)
FIG. 14 Global Pharmaceutical CRO and CDMO Market, by Active Pharmaceutical Ingredient (API) Manufacturing, Value, 2017-2030 (US$ Bn)
FIG. 15 Global Pharmaceutical CRO and CDMO Market, by Secondary Packaging, Value, 2017-2030 (US$ Bn)
FIG. 16 Global Pharmaceutical CRO and CDMO Market Value Contribution, By Research Phase, 2022 & 2030 (Value %)
FIG. 17 Global Pharmaceutical CRO and CDMO Market, by Pre-clinical, Value, 2017-2030 (US$ Bn)
FIG. 18 Global Pharmaceutical CRO and CDMO Market, by Phase I, 2017-2030 (US$ Bn)
FIG. 19 Global Pharmaceutical CRO and CDMO Market, by Phase II, 2017-2030 (US$ Bn)
FIG. 20 Global Pharmaceutical CRO and CDMO Market, by Phase III, 2017-2030 (US$ Bn)
FIG. 21 Global Pharmaceutical CRO and CDMO Market, by Phase IV, 2017-2030 (US$ Bn)
FIG. 22 North America Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 23 U.S. Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 24 Canada Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 25 Europe Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 26 Germany Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 27 France Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 28 U.K. Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 29 Italy Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 30 Spain Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 31 Rest of Europe Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 32 Asia Pacific Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 33 China Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 34 Japan Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 35 India Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 36 South Korea Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 37 South-East Asia Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 38 Rest of Asia Pacific Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 39 Latin America Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 40 Brazil Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 41 Mexico Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 42 Rest of Latin America Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 43 Middle East & Africa Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 44 GCC Countries Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 45 South Africa Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)
FIG. 46 Rest of Middle East and Africa Pharmaceutical CRO and CDMO Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Pharmaceutical CRO and CDMO Market
TABLE 2 Global Pharmaceutical CRO and CDMO Market: Market Drivers Impact Analysis
TABLE 3 Global Pharmaceutical CRO and CDMO Market: Market Restraints Impact Analysis
TABLE 4 Global Pharmaceutical CRO and CDMO Market, by Competitive Benchmarking, 2022
TABLE 5 Global Pharmaceutical CRO and CDMO Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Pharmaceutical CRO and CDMO Market, by Key Strategies Analysis, 2022
TABLE 7 Global Pharmaceutical CRO and CDMO Market, by Active Pharmaceutical Ingredient (API) Manufacturing, By Region, 2017-2022 (US$ Bn)
TABLE 8 Global Pharmaceutical CRO and CDMO Market, by Active Pharmaceutical Ingredient (API) Manufacturing, By Region, 2023-2030 (US$ Bn)
TABLE 9 Global Pharmaceutical CRO and CDMO Market, by Active Pharmaceutical Ingredient (API) Manufacturing, By Region, 2017-2022 (US$ Bn)
TABLE 10 Global Pharmaceutical CRO and CDMO Market, by Active Pharmaceutical Ingredient (API) Manufacturing, By Region, 2023-2030 (US$ Bn)
TABLE 11 Global Pharmaceutical CRO and CDMO Market, by Secondary Packaging, By Region, 2017-2022 (US$ Bn)
TABLE 12 Global Pharmaceutical CRO and CDMO Market, by Secondary Packaging, By Region, 2023-2030 (US$ Bn)
TABLE 13 Global Pharmaceutical CRO and CDMO Market, by Pre-clinical, By Region, 2017-2022 (US$ Bn)
TABLE 14 Global Pharmaceutical CRO and CDMO Market, by Pre-clinical, By Region, 2023-2030 (US$ Bn)
TABLE 15 Global Pharmaceutical CRO and CDMO Market, by Phase I, By Region, 2017-2022 (US$ Bn)
TABLE 16 Global Pharmaceutical CRO and CDMO Market, by Phase I, By Region, 2023-2030 (US$ Bn)
TABLE 17 Global Pharmaceutical CRO and CDMO Market, by Phase II, By Region, 2017-2022 (US$ Bn)
TABLE 18 Global Pharmaceutical CRO and CDMO Market, by Phase II, By Region, 2023-2030 (US$ Bn)
TABLE 19 Global Pharmaceutical CRO and CDMO Market, by Phase III, By Region, 2017-2022 (US$ Bn)
TABLE 20 Global Pharmaceutical CRO and CDMO Market, by Phase III, By Region, 2023-2030 (US$ Bn)
TABLE 21 Global Pharmaceutical CRO and CDMO Market, by Phase IV, By Region, 2017-2022 (US$ Bn)
TABLE 22 Global Pharmaceutical CRO and CDMO Market, by Phase IV, By Region, 2023-2030 (US$ Bn)
TABLE 23 Global Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 24 Global Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 25 Global Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 26 Global Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 27 Global Pharmaceutical CRO and CDMO Market, by Region, 2017-2022 (US$ Bn)
TABLE 28 Global Pharmaceutical CRO and CDMO Market, by Region, 2023-2030 (US$ Bn)
TABLE 29 North America Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 30 North America Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 31 North America Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 32 North America Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 33 North America Pharmaceutical CRO and CDMO Market, by Country, 2017-2022 (US$ Bn)
TABLE 34 North America Pharmaceutical CRO and CDMO Market, by Country, 2023-2030 (US$ Bn)
TABLE 35 United States Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 36 United States Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 37 United States Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 38 United States Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 39 Canada Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 40 Canada Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 41 Canada Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 42 Canada Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 43 Mexico Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 44 Mexico Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 45 Mexico Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 46 Mexico Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 47 Europe Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 48 Europe Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 49 Europe Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 50 Europe Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 51 Europe Pharmaceutical CRO and CDMO Market, by Country, 2017-2022 (US$ Bn)
TABLE 52 Europe Pharmaceutical CRO and CDMO Market, by Country, 2023-2030 (US$ Bn)
TABLE 53 Germany Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 54 Germany Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 55 Germany Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 56 Germany Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 57 France Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 58 France Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 59 France Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 60 France Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 61 United Kingdom Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 62 United Kingdom Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 63 United Kingdom Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 64 United Kingdom Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 65 Italy Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 66 Italy Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 67 Italy Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 68 Italy Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 69 Spain Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 70 Spain Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 71 Spain Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 72 Spain Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 73 Rest of Europe Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 74 Rest of Europe Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 75 Rest of Europe Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 76 Rest of Europe Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 77 Asia Pacific Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 78 Asia Pacific Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 79 Asia Pacific Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 80 Asia Pacific Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 81 China Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 82 China Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 83 China Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 84 China Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 85 Japan Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 86 Japan Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 87 Japan Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 88 Japan Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 89 India Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 90 India Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 91 India Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 92 India Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 93 South Korea Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 94 South Korea Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 95 South Korea Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 96 South Korea Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 97 South-East Asia Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 98 South-East Asia Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 99 South-East Asia Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 100 South-East Asia Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 101 Rest of Asia Pacific Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 102 Rest of Asia Pacific Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 103 Rest of Asia Pacific Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 104 Rest of Asia Pacific Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 105 Latin America Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 106 Latin America Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 107 Latin America Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 108 Latin America Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 109 Brazil Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 110 Brazil Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 111 Brazil Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 112 Brazil Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 113 Argentina Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 114 Argentina Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 115 Argentina Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 116 Argentina Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 117 Rest of Latin America Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 118 Rest of Latin America Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 119 Rest of Latin America Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 120 Rest of Latin America Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 121 Middle East and Africa Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 122 Middle East and Africa Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 123 Middle East and Africa Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 124 Middle East and Africa Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 125 GCC Countries Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 126 GCC Countries Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 127 GCC Countries Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 128 GCC Countries Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 129 South Africa Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 130 South Africa Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 131 South Africa Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 132 South Africa Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)
TABLE 133 Rest of Middle East and Africa Pharmaceutical CRO and CDMO Market, by Service Type, 2017-2022 (US$ Bn)
TABLE 134 Rest of Middle East and Africa Pharmaceutical CRO and CDMO Market, by Service Type, 2023-2030 (US$ Bn)
TABLE 135 Rest of Middle East and Africa Pharmaceutical CRO and CDMO Market, by Research Phase, 2017-2022 (US$ Bn)
TABLE 136 Rest of Middle East and Africa Pharmaceutical CRO and CDMO Market, by Research Phase, 2023-2030 (US$ Bn)

Frequently Asked Questions

What is the current size of the global Pharmaceutical CRO and CDMO market?

The global Pharmaceutical CRO and CDMO market was valued at USD 308.9 Billion in 2022.

What is the expected growth rate of the Pharmaceutical CRO and CDMO market between 2023 and 2030?

The Pharmaceutical CRO and CDMO market is expected to grow at a CAGR of 1.30% between 2023 and 2030, reaching USD 338.13 Billion in 2030.

Which segment is leading the market share in terms of service type?

The largest market segment is API manufacturing, which accounted for 55.6% of the total market in 2022.

Which research phase segment governs the demand for Pharmaceutical CROs and CDMOs worldwide?

The largest market segment is phase III, which accounted for 44.2% of the total market 2022.

Which segment is expected to post the highest CAGR during the forecast period?

The fastest growing market segment is phase IV, expected to grow at the fastest CAGR from 2023 to 2030.

Which region is fueling the growth of the Pharmaceutical CRO and CDMO industry?

The largest market in 2022 was North America of the global Pharmaceutical CRO and CDMO market.

Who are the major players in the global Pharmaceutical CRO and CDMO market?

The top players include Catalent Inc., Recipharm AB, Jubilant Pharmova Ltd, Patheon Inc. (Thermo Fisher Scientific Inc.), Boehringer Ingelheim Group, Pfizer CentreSource, Aenova Holding GmbH, Famar SA, Baxter Biopharma Solutions (Baxter International Inc.), Lonza Group, Tesa Labtec GmbH (TESA SE), Tapemark, ARX LLC, CMIC Holdings Co. Ltd, LabCorp Drug Development, Syneos Health Inc., and Novotech Pty Ltd.

What are the major market drivers of the Pharmaceutical CRO and CDMO industry?

The increasing demand for new drugs, the rising cost of drug development, and increasingly outsourcing development and manufacturing activities are the major market drivers.

What are the major market restraints of the Pharmaceutical CRO and CDMO industry?

Stringent regulations and complex supply chains are the major market restraints.

What are the major market opportunities of the Pharmaceutical CRO and CDMO industry?

The growing demand for new drugs to treat chronic diseases and the growing focus on personalized medicine are the major opportunities in the Pharmaceutical CRO and CDMO industry.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –